Evidence map›Paper›PMID 35334078›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2022

Research progress on epigenetics of small B-cell lymphoma.

Xueqin Ruan, Rong Zhang, Hongkai Zhu, Can Ye, Zhihua Wang, En Dong, Ruijuan Li, Zhao Cheng, Hongling Peng

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Xueqin RuanDepartment of Hematology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Rong ZhangDivision of Cancer Immunotherapy, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Chiba, Japan.
Hongkai ZhuDepartment of Hematology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Can YeDepartment of Hematology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhihua WangDepartment of Hematology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
En DongBlood Center, Changsha, Hunan, China.
Ruijuan LiDepartment of Hematology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. ruijuanli@csu.edu.cn.
Zhao ChengDepartment of Hematology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. chengzhao@csu.edu.cn.ORCID http://orcid.org/0000-0002-5801-1517
Hongling PengDepartment of Hematology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Central South University · CNChiba Cancer Center · JP

Funding

Changsha Municipal Natural Science Foundation kq2014234National Natural Science Foundation of China 82070175Natural Science Foundation of Hunan Province 2021JJ30937Scientific program of Health Commission of Hunan Province 2022030442723
6 · The paper itself

Abstract

Small B-cell lymphoma is the classification of B-cell chronic lymphoproliferative disorders that include chronic lymphocytic leukaemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. The clinical presentation is somewhat heterogeneous, and its occurrence and development mechanisms are not yet precise and may involve epigenetic changes. Epigenetic alterations mainly include DNA methylation, histone modification, and non-coding RNA, which are essential for genetic detection, early diagnosis, and assessment of treatment resistance in small B-cell lymphoma. As chronic lymphocytic leukemia/small lymphocytic lymphoma has already been reported in the literature, this article focuses on small B-cell lymphomas such as follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and Waldenstrom macroglobulinemia. It discusses recent developments in epigenetic research to diagnose and treat this group of lymphomas. This review provides new ideas for the treatment and prognosis assessment of small B-cell lymphoma by exploring the connection between small B-cell lymphoma and epigenetics.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, B-Cell, Marginal ZoneLymphoma, FollicularLymphoma, Mantle-CellWaldenstrom MacroglobulinemiaAdultEpigenesis, GeneticHumansDNA methylationEpigeneticsHistone modificationNon-coding RNASmall B-cell lymphoma

Identifiers

PMID35334078
OpenAlexW4220881043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.